{"id":32230,"date":"2025-04-22T18:23:32","date_gmt":"2025-04-22T10:23:32","guid":{"rendered":"https:\/\/flcube.com\/?p=32230"},"modified":"2025-04-22T18:23:33","modified_gmt":"2025-04-22T10:23:33","slug":"viatris-submits-marketing-application-for-effexor-sr-in-japan-for-generalized-anxiety-disorder","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=32230","title":{"rendered":"Viatris Submits Marketing Application for Effexor SR in Japan for Generalized Anxiety Disorder"},"content":{"rendered":"\n

Viatris Inc. (NASDAQ: VTRS<\/a>) announced the submission of a marketing application to Japan’s Ministry of Health, Labour and Welfare (MHLW) for Effexor SR (venlafaxine hydrochloride extended-release), a serotonin-norepinephrine reuptake inhibitor (SNRI). This application seeks approval for the treatment of generalized anxiety disorder (GAD) in adults, an indication for which no therapies are currently approved in Japan.<\/p>\n\n\n\n

Global Context and Effexor\u2019s Position<\/strong>
Globally, selective serotonin reuptake inhibitors (SSRIs) and SNRIs are recommended as first-line treatments for GAD. Effexor is already approved in Japan for major depressive disorder (MDD) in adults. Outside Japan, Effexor holds GAD approvals in over 80 countries, underscoring its established role in mental health treatment.<\/p>\n\n\n\n

Market and Patient Impact<\/strong>
The submission highlights Viatris’s commitment to addressing unmet medical needs in Japan. If approved, Effexor SR would offer a new treatment option for adults with GAD, aligning with global standards of care and potentially improving patient outcomes in a market lacking approved therapies for this condition.-Fineline Info & Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"

Viatris Inc. (NASDAQ: VTRS) announced the submission of a marketing application to Japan’s Ministry of…<\/p>\n","protected":false},"author":1,"featured_media":32231,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[38,1018,207],"class_list":["post-32230","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-drug","tag-market-approval-filings","tag-nasdaq-vtrs","tag-viatris"],"yoast_head":"\nViatris Submits Marketing Application for Effexor SR in Japan for Generalized Anxiety Disorder - Insight, China's Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Viatris Inc. (NASDAQ: VTRS) announced the submission of a marketing application to Japan\u2019s Ministry of Health, Labour and Welfare (MHLW) for Effexor SR (venlafaxine hydrochloride extended-release), a serotonin-norepinephrine reuptake inhibitor (SNRI). This application seeks approval for the treatment of generalized anxiety disorder (GAD) in adults, an indication for which no therapies are currently approved in Japan.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=32230\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Viatris Submits Marketing Application for Effexor SR in Japan for Generalized Anxiety Disorder\" \/>\n<meta property=\"og:description\" content=\"Viatris Inc. (NASDAQ: VTRS) announced the submission of a marketing application to Japan\u2019s Ministry of Health, Labour and Welfare (MHLW) for Effexor SR (venlafaxine hydrochloride extended-release), a serotonin-norepinephrine reuptake inhibitor (SNRI). This application seeks approval for the treatment of generalized anxiety disorder (GAD) in adults, an indication for which no therapies are currently approved in Japan.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=32230\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China's Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-04-22T10:23:32+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-04-22T10:23:33+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/04\/2217.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=32230#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=32230\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Viatris Submits Marketing Application for Effexor SR in Japan for Generalized Anxiety Disorder\",\"datePublished\":\"2025-04-22T10:23:32+00:00\",\"dateModified\":\"2025-04-22T10:23:33+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=32230\"},\"wordCount\":176,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=32230#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/04\\\/2217.webp\",\"keywords\":[\"Market approval filings\",\"NASDAQ: VTRS\",\"Viatris\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=32230#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=32230\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=32230\",\"name\":\"Viatris Submits Marketing Application for Effexor SR in Japan for Generalized Anxiety Disorder - Insight, China's Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=32230#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=32230#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/04\\\/2217.webp\",\"datePublished\":\"2025-04-22T10:23:32+00:00\",\"dateModified\":\"2025-04-22T10:23:33+00:00\",\"description\":\"Viatris Inc. (NASDAQ: VTRS) announced the submission of a marketing application to Japan\u2019s Ministry of Health, Labour and Welfare (MHLW) for Effexor SR (venlafaxine hydrochloride extended-release), a serotonin-norepinephrine reuptake inhibitor (SNRI). This application seeks approval for the treatment of generalized anxiety disorder (GAD) in adults, an indication for which no therapies are currently approved in Japan.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=32230#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=32230\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=32230#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/04\\\/2217.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/04\\\/2217.webp\",\"width\":1080,\"height\":608,\"caption\":\"Viatris Submits Marketing Application for Effexor SR in Japan for Generalized Anxiety Disorder\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=32230#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Viatris Submits Marketing Application for Effexor SR in Japan for Generalized Anxiety Disorder\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Viatris Submits Marketing Application for Effexor SR in Japan for Generalized Anxiety Disorder - Insight, China's Pharmaceutical Industry","description":"Viatris Inc. (NASDAQ: VTRS) announced the submission of a marketing application to Japan\u2019s Ministry of Health, Labour and Welfare (MHLW) for Effexor SR (venlafaxine hydrochloride extended-release), a serotonin-norepinephrine reuptake inhibitor (SNRI). This application seeks approval for the treatment of generalized anxiety disorder (GAD) in adults, an indication for which no therapies are currently approved in Japan.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=32230","og_locale":"en_US","og_type":"article","og_title":"Viatris Submits Marketing Application for Effexor SR in Japan for Generalized Anxiety Disorder","og_description":"Viatris Inc. (NASDAQ: VTRS) announced the submission of a marketing application to Japan\u2019s Ministry of Health, Labour and Welfare (MHLW) for Effexor SR (venlafaxine hydrochloride extended-release), a serotonin-norepinephrine reuptake inhibitor (SNRI). This application seeks approval for the treatment of generalized anxiety disorder (GAD) in adults, an indication for which no therapies are currently approved in Japan.","og_url":"https:\/\/flcube.com\/?p=32230","og_site_name":"Insight, China's Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-04-22T10:23:32+00:00","article_modified_time":"2025-04-22T10:23:33+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/04\/2217.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=32230#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=32230"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Viatris Submits Marketing Application for Effexor SR in Japan for Generalized Anxiety Disorder","datePublished":"2025-04-22T10:23:32+00:00","dateModified":"2025-04-22T10:23:33+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=32230"},"wordCount":176,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=32230#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/04\/2217.webp","keywords":["Market approval filings","NASDAQ: VTRS","Viatris"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=32230#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=32230","url":"https:\/\/flcube.com\/?p=32230","name":"Viatris Submits Marketing Application for Effexor SR in Japan for Generalized Anxiety Disorder - Insight, China's Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=32230#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=32230#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/04\/2217.webp","datePublished":"2025-04-22T10:23:32+00:00","dateModified":"2025-04-22T10:23:33+00:00","description":"Viatris Inc. (NASDAQ: VTRS) announced the submission of a marketing application to Japan\u2019s Ministry of Health, Labour and Welfare (MHLW) for Effexor SR (venlafaxine hydrochloride extended-release), a serotonin-norepinephrine reuptake inhibitor (SNRI). This application seeks approval for the treatment of generalized anxiety disorder (GAD) in adults, an indication for which no therapies are currently approved in Japan.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=32230#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=32230"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=32230#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/04\/2217.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/04\/2217.webp","width":1080,"height":608,"caption":"Viatris Submits Marketing Application for Effexor SR in Japan for Generalized Anxiety Disorder"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=32230#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Viatris Submits Marketing Application for Effexor SR in Japan for Generalized Anxiety Disorder"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/04\/2217.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/32230","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=32230"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/32230\/revisions"}],"predecessor-version":[{"id":32232,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/32230\/revisions\/32232"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/32231"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=32230"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=32230"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=32230"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}